{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:57:50Z","timestamp":1792000670638,"version":"4.4.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Bristol Myers Squibb"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40119-024-00396-z","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T11:00:14Z","timestamp":1736938814000},"page":"71-86","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prevalence, Patient Characteristics, and Treatment of Patients with Hypertrophic Cardiomyopathy: A Nationwide Payer Database Study"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5303-3186","authenticated-orcid":false,"given":"Yuika","family":"Ikeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5241-9482","authenticated-orcid":false,"given":"Tsunehisa","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8208-4823","authenticated-orcid":false,"given":"Makio","family":"Torigoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2366-0960","authenticated-orcid":false,"given":"Bruno","family":"Casaes Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7053-8469","authenticated-orcid":false,"given":"Thomas","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"key":"396_CR1","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","volume":"44","author":"E Arbelo","year":"2023","unstructured":"Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, et al. 2023 ESC guidelines for the management of cardiomyopathies: developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC). Eur Heart J. 2023;44:3503\u2013626.","journal-title":"Eur Heart J"},{"key":"396_CR2","doi-asserted-by":"publisher","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","volume":"149","author":"SR Ommen","year":"2024","unstructured":"Ommen SR, Ho CY, Asif IM, Balaji S, Burke MA, Day SM, et al. 2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology joint committee on clinical practice guidelines. Circulation. 2024;149:e1239\u2013311.","journal-title":"Circulation"},{"key":"396_CR3","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1253\/circj.CJ-20-0910","volume":"85","author":"H Kitaoka","year":"2021","unstructured":"Kitaoka H, Tsutsui H, Kubo T, Ide T, Chikamori T, Fukuda K, et al. JCS\/JHFS 2018 guideline on the diagnosis and treatment of cardiomyopathies. Circulation. 2021;85:1590\u2013689.","journal-title":"Circulation"},{"key":"396_CR4","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1056\/NEJMra1710575","volume":"379","author":"BJ Maron","year":"2018","unstructured":"Maron BJ. Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med. 2018;379:655\u201368.","journal-title":"N Engl J Med"},{"key":"396_CR5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.amjcard.2021.08.024","volume":"159","author":"M Butzner","year":"2021","unstructured":"Butzner M, Maron M, Sarocco P, Rowin E, Teng C-C, Tan H, et al. Clinical diagnosis of hypertrophic cardiomyopathy over time in the United States (a population-based claims analysis). Am J Card. 2021;159:107\u201312.","journal-title":"Am J Card"},{"key":"396_CR6","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jjcc.2022.09.015","volume":"81","author":"N Terasaka","year":"2023","unstructured":"Terasaka N, Spanopoulos D, Miyagoshi H, Kubo T, Kitaoka H. Estimating the prevalence, clinical characteristics, and treatment patterns of hypertrophic cardiomyopathy in Japan: a nationwide medical claims database study. J Cardiol. 2023;81:316\u201322.","journal-title":"J Cardiol"},{"key":"396_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac544.1747","volume":"43","author":"M Schultze","year":"2022","unstructured":"Schultze M, Zema C, Carroll R, Hurst M, Borchert J, Zhong Y, et al. Population estimates of obstructive and non-obstructive hypertrophic cardiomyopathy in the UK and Germany. Eur Heart J. 2022;43: ehac544.1747.","journal-title":"Eur Heart J"},{"key":"396_CR8","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1016\/j.amjcard.2016.02.044","volume":"117","author":"MS Maron","year":"2016","unstructured":"Maron MS, Hellawell JL, Lucove JC, Farzaneh-Far R, Olivotto I. Occurrence of clinically diagnosed hypertrophic cardiomyopathy in the United States. Am J Cardiol. 2016;117:1651\u20134.","journal-title":"Am J Cardiol"},{"key":"396_CR9","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1136\/heart.87.2.126","volume":"87","author":"K Miura","year":"2002","unstructured":"Miura K, Nakagawa H, Morikawa Y, Sasayama S, Matsumori A, Hasegawa K, et al. Epidemiology of idiopathic cardiomyopathy in Japan: results from a nationwide survey. Heart. 2002;87:126.","journal-title":"Heart"},{"key":"396_CR10","unstructured":"Health Insurance Bureau, Ministry of Health, Labour and Welfare. Basic data on medical insurance. https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/iryouhoken\/database\/zenpan\/kiso.html. Accessed Aug 2024."},{"key":"396_CR11","first-page":"190","volume":"5","author":"A Okada","year":"2022","unstructured":"Okada A, Yasunaga H. Prevalence of noncommunicable diseases in Japan using a newly developed administrative claims database covering young, middle-aged, and elderly people. JMA J. 2022;5:190\u20138.","journal-title":"JMA J"},{"key":"396_CR12","unstructured":"JMDC Inc. JMDC claims database https:\/\/www.jmdc.co.jp\/en\/jmdc-claims-database\/ (accessed Aug 2024)."},{"key":"396_CR13","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1248\/bpb.b24-00153","volume":"47","author":"J Tomida","year":"2024","unstructured":"Tomida J, Wasa C, Hirata M, Ichihara M, Kawazoe T, Iihara N. Quantification of oversupply of chronic disease medications among patients aged \u226555 years in Japan. Biol Pharm Bull. 2024;47:1128\u201335.","journal-title":"Biol Pharm Bull"},{"key":"396_CR14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.007230","volume":"13","author":"M Canepa","year":"2020","unstructured":"Canepa M, Fumagalli C, Tini G, Vincent-Tompkins J, Day SM, Ashley EA, et al. Temporal trend of age at diagnosis in hypertrophic cardiomyopathy. Circ Heart Fail. 2020;13: e007230.","journal-title":"Circ Heart Fail"},{"key":"396_CR15","unstructured":"D Statis. Statistishes bundesamt. https:\/\/www.destatis.de\/EN\/Themes\/Society-Environment\/Population\/Current-Population\/_node.html#1346190. Accessed Sep 2024."},{"key":"396_CR16","unstructured":"E-Stat. Statistics of Japan. Population estimates by age (5-year age group) and sex - total population, Japanese population https:\/\/www.e-stat.go.jp\/en\/stat-search\/files?page=1&layout=datalist&toukei=00200524&tstat=000000090001&cycle=0&year=20210&month=0&tclass1=000001011678&tclass2=000001161226&tclass3val=0. Accessed Sep 2024."},{"key":"396_CR17","unstructured":"Gov.UK. UK population by ethnicity. https:\/\/www.ethnicity-facts-figures.service.gov.uk\/uk-population-by-ethnicity\/demographics\/age-groups\/latest\/. Accessed Sep 2024."},{"key":"396_CR18","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.hlc.2023.10.021","volume":"33","author":"D Playford","year":"2024","unstructured":"Playford D, Strange GA, Atherton JJ, Harris S, Chan Y-K, Stewart S. Clinical to population prevalence of hypertrophic cardiomyopathy phenotype: insights from the national echo database Australia. Heart Lung Circ. 2024;33:212\u201321.","journal-title":"Heart Lung Circ"},{"key":"396_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.765876","volume":"8","author":"M Butzner","year":"2022","unstructured":"Butzner M, Leslie DL, Cuffee Y, Hollenbeak CS, Sciamanna C, Abraham T. Stable rates of obstructive hypertrophic cardiomyopathy in a contemporary era. Front Cardiovasc Med. 2022;8: 765876.","journal-title":"Front Cardiovasc Med"},{"key":"396_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0196612","volume":"13","author":"D Husser","year":"2018","unstructured":"Husser D, Ueberham L, Jacob J, Heuer D, Riedel-Heller S, Walker J, et al. Prevalence of clinically apparent hypertrophic cardiomyopathy in Germany\u2014an analysis of over 5 million patients. PLoS ONE. 2018;13: e0196612.","journal-title":"PLoS ONE"},{"key":"396_CR21","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1161\/hc0402.102990","volume":"105","author":"H Niimura","year":"2002","unstructured":"Niimura H, Patton KK, McKenna WJ, Soults J, Maron BJ, Seidman JG, et al. Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly. Circulation. 2002;105:446\u201351.","journal-title":"Circulation"},{"key":"396_CR22","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.amjcard.2022.06.017","volume":"179","author":"BA Maron","year":"2022","unstructured":"Maron BA, Wang R-S, Carnethon MR, Rowin EJ, Loscalzo J, Maron BJ, et al. What causes hypertrophic cardiomyopathy? Am J Cardiol. 2022;179:74\u201382.","journal-title":"Am J Cardiol"},{"key":"396_CR23","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jjcc.2010.07.004","volume":"56","author":"T Kubo","year":"2010","unstructured":"Kubo T, Kitaoka H, Okawa M, Hirota T, Hayato K, Yamasaki N, et al. Gender-specific differences in the clinical features of hypertrophic cardiomyopathy in a community-based Japanese population: results from Kochi RYOMA study. J Cardiol. 2010;56:314\u20139.","journal-title":"J Cardiol"},{"key":"396_CR24","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1159\/000517618","volume":"9","author":"A Trongtorsak","year":"2021","unstructured":"Trongtorsak A, Polpichai N, Thangjui S, Kewcharoen J, Yodsuwan R, Devkota A, et al. Gender-related differences in hypertrophic cardiomyopathy: a systematic review and meta-analysis. Pulse. 2021;9:38\u201346.","journal-title":"Pulse"},{"key":"396_CR25","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jchf.2018.12.018","volume":"7","author":"PZ Maslov","year":"2019","unstructured":"Maslov PZ, Kim JK, Argulian E, Ahmadi A, Narula N, Singh M, et al. Is cardiac diastolic dysfunction a part of post-menopausal syndrome? JACC Heart Failure. 2019;7:192\u2013203.","journal-title":"JACC Heart Failure"},{"key":"396_CR26","first-page":"H628","volume":"306","author":"Z Zhao","year":"2014","unstructured":"Zhao Z, Wang H, Jessup JA, Lindsey SH, Chappell MC, Groban L. Role of estrogen in diastolic dysfunction. Am J Physiol. 2014;306:H628\u201340.","journal-title":"Am J Physiol"},{"key":"396_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/ehaa946.2085","volume":"41","author":"T Kubo","year":"2020","unstructured":"Kubo T, Takano H, Takayama M, Doi YL, Minami Y, Ebato M, et al. Baseline clinical features in a large-scale registration survey of patient with hypertrophic cardiomyopathy throughout Japan: J-HCM registry study. Eur Heart J. 2020;41: ehaa946.2085.","journal-title":"Eur Heart J"},{"key":"396_CR28","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jacc.2005.04.043","volume":"46","author":"I Olivotto","year":"2005","unstructured":"Olivotto I, Maron MS, Adabag AS, Casey SA, Vargiu D, Link MS, et al. Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46:480\u20137.","journal-title":"J Am Coll Cardiol"},{"key":"396_CR29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0167-5273(00)00401-0","volume":"77","author":"PP Dimitrow","year":"2001","unstructured":"Dimitrow PP, Czarnecka D, Strojny JA, Kawecka-Jaszcz K, Dubiel JS. Impact of gender on the left ventricular cavity size and contractility in patients with hypertrophic cardiomyopathy. Int J Cardiol. 2001;77:43\u20138.","journal-title":"Int J Cardiol"},{"key":"396_CR30","volume":"122","author":"I Ranasinghe","year":"2010","unstructured":"Ranasinghe I, Cheruvu C, Yiannikas J. Abstract 18951: Is sigmoid septum an age related phenomenon or a variant of hypertrophic cardiomyopathy? Circulation. 2010;122: A18951-A.","journal-title":"Circulation"},{"key":"396_CR31","first-page":"105","volume":"1","author":"NDR Walhin","year":"2018","unstructured":"Walhin NDR, Bonnet P, Petitjean H, Radermecker A, Legrand V, Lancelloti P, Radermecker MA. HOCM\/Sigmoid septum: mechanism and management of the obstruction. GSL Cardiovasc Dis. 2018;1:105.","journal-title":"GSL Cardiovasc Dis"},{"key":"396_CR32","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jccase.2020.05.019","volume":"22","author":"T Hamana","year":"2020","unstructured":"Hamana T, Iwasaki M, Otake H, Kokawa T, Fukuishi Y, Odajima S, et al. A successful case of percutaneous transluminal septal myocardial ablation for left ventricular outflow tract obstruction caused by sigmoid septum. J Cardiol Cases. 2020;22:159\u201362.","journal-title":"J Cardiol Cases"},{"key":"396_CR33","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1253\/circj.CJ-09-0140","volume":"73","author":"T Kubo","year":"2009","unstructured":"Kubo T, Kitaoka H, Okawa M, Hirota T, Hayato K, Yamasaki N, et al. Clinical impact of atrial fibrillation in patients with hypertrophic cardiomyopathy results from Kochi RYOMA study. Circulation. 2009;73:1599\u2013605.","journal-title":"Circulation"},{"key":"396_CR34","unstructured":"Ministry of Health, Labour and Welfare. Patient Survey 2020 https:\/\/www.mhlw.go.jp\/toukei\/list\/10-20-kekka_gaiyou.html (accessed Aug 2024)."},{"key":"396_CR35","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.3390\/biomedicines12071602","volume":"12","author":"R Mistrulli","year":"2024","unstructured":"Mistrulli R, Ferrera A, Salerno L, Vannini F, Guida L, Corradetti S, et al. Cardiomyopathy and sudden cardiac death: bridging clinical practice with cutting-edge research. Biomedicines. 2024;12:1602.","journal-title":"Biomedicines"},{"key":"396_CR36","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1136\/heartjnl-2013-304276","volume":"100","author":"OP Guttmann","year":"2014","unstructured":"Guttmann OP, Rahman MS, Mahony C, Anastasakis A, Elliott PM. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. Heart. 2014;100:465.","journal-title":"Heart"},{"key":"396_CR37","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ijcard.2008.06.029","volume":"137","author":"H Inoue","year":"2009","unstructured":"Inoue H, Fujiki A, Origasa H, Ogawa S, Okumura K, Kubota I, et al. Prevalence of atrial fibrillation in the general population of Japan: an analysis based on periodic health examination. Int J Cardiol. 2009;137:102\u20137.","journal-title":"Int J Cardiol"},{"key":"396_CR38","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s40256-024-00674-0","volume":"24","author":"M Butzner","year":"2024","unstructured":"Butzner M, Papademetriou E, Potluri R, Liu X, Shreay S. Differences in healthcare resource use and cost by pharmacotherapy among patients with symptomatic obstructive hypertrophic cardiomyopathy: real-world analysis of claims data. Am J Cardiovasc Drugs. 2024;24:801\u201311.","journal-title":"Am J Cardiovasc Drugs"},{"key":"396_CR39","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40119-022-00257-7","volume":"11","author":"AT Owens","year":"2022","unstructured":"Owens AT, Sutton MB, Gao W, Fine JT, Xie J, Naidu SS, et al. Treatment changes, healthcare resource utilization, and costs among patients with symptomatic obstructive hypertrophic cardiomyopathy: a claims database study. Cardiol Ther. 2022;11:249\u201367.","journal-title":"Cardiol Ther"},{"key":"396_CR40","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.cardfail.2021.04.023","volume":"27","author":"H Tsutsui","year":"2021","unstructured":"Tsutsui H, Ide T, Ito H, Kihara Y, Kinugawa K, Kinugawa S, et al. JCS\/JHFS 2021 guideline focused update on diagnosis and treatment of acute and chronic heart failure. J Card Fail. 2021;27:1404\u201344.","journal-title":"J Card Fail"},{"key":"396_CR41","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/joa3.12714","volume":"38","author":"K Ono","year":"2022","unstructured":"Ono K, Iwasaki Y-k, Akao M, Ikeda T, Ishii K, Inden Y, et al. JCS\/JHRS 2020 guideline on pharmacotherapy of cardiac arrhythmias. J Arrhythmia. 2022;38:833\u2013973.","journal-title":"J Arrhythmia"},{"key":"396_CR42","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res. 2019;42:1235\u2013481.","journal-title":"Hypertens Res"},{"key":"396_CR43","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/pcn.12894","volume":"73","author":"D Nishi","year":"2019","unstructured":"Nishi D, Ishikawa H, Kawakami N. Prevalence of mental disorders and mental health service use in Japan. Psychiatry Clin Neurosci. 2019;73:458\u201365.","journal-title":"Psychiatry Clin Neurosci"},{"key":"396_CR44","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.jad.2018.08.050","volume":"241","author":"H Ishikawa","year":"2018","unstructured":"Ishikawa H, Tachimori H, Takeshima T, Umeda M, Miyamoto K, Shimoda H, et al. Prevalence, treatment, and the correlates of common mental disorders in the mid-2010s in Japan: the results of the World Mental Health Japan 2nd survey. J Affect Disord. 2018;241:554\u201362.","journal-title":"J Affect Disord"},{"key":"396_CR45","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/eurjpc\/zwac260","volume":"30","author":"J-B Park","year":"2023","unstructured":"Park J-B, Yun J-Y, Kim B, Rhee T-M, Lee H-J, Lee H, et al. Risk of incident mental disorders in hypertrophic cardiomyopathy: a nationwide propensity-matched study. Eur J Prev Cardiol. 2023;30:85\u201394.","journal-title":"Eur J Prev Cardiol"},{"key":"396_CR46","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.genhosppsych.2007.09.005","volume":"30","author":"JF Morgan","year":"2008","unstructured":"Morgan JF, O\u2019Donoghue AC, McKenna WJ, Schmidt MM. Psychiatric disorders in hypertrophic cardiomyopathy. Gen Hosp Psychiatry. 2008;30:49\u201354.","journal-title":"Gen Hosp Psychiatry"},{"key":"396_CR47","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s41687-020-00269-8","volume":"4","author":"E Zaiser","year":"2020","unstructured":"Zaiser E, Sehnert AJ, Duenas A, Saberi S, Brookes E, Reaney M. Patient experiences with hypertrophic cardiomyopathy: a conceptual model of symptoms and impacts on quality of life. J Patient Rep Outcomes. 2020;4:102.","journal-title":"J Patient Rep Outcomes"},{"key":"396_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.890506","volume":"9","author":"C-J He","year":"2022","unstructured":"He C-J, Zhai C-L, Huang S-D, Fan H-Y, Qian Y-Z, Zhu C-Y, et al. Anxiety predicts poor prognosis in patients with hypertrophic cardiomyopathy. Front Cardiovasc Med. 2022;9: 890506.","journal-title":"Front Cardiovasc Med"},{"key":"396_CR49","unstructured":"Japan Intractable Diseases Information Center. FY2021 Hygiene Administration Report https:\/\/www.nanbyou.or.jp\/wp-content\/uploads\/2023\/02\/koufu20221.pdf. Accessed Jul 2024."},{"key":"396_CR50","unstructured":"Japan Intractable Diseases Information Center. Number of recipients of special medical expenses (designated intractable disease) certificates https:\/\/www.nanbyou.or.jp\/entry\/5354. Accessed Nov 2024."},{"key":"396_CR51","unstructured":"Ministry of Health, Labour and Welfare. 2023 Annual Health, Labour and Welfare Report. https:\/\/www.mhlw.go.jp\/wp\/hakusyo\/kousei\/22-2\/dl\/01.pdf. Accessed Sep 2024."}],"updated-by":[{"DOI":"10.1007\/s40119-025-00414-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000}}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-024-00396-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-024-00396-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-024-00396-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T07:02:58Z","timestamp":1747810978000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-024-00396-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["396"],"URL":"https:\/\/doi.org\/10.1007\/s40119-024-00396-z","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40119-025-00414-8","asserted-by":"object"}]},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]},"assertion":[{"value":"18 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Revised version of supplementary file updated","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40119-025-00414-8","URL":"https:\/\/doi.org\/10.1007\/s40119-025-00414-8","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yuika Ikeda, Tsunehisa Yamamoto, Makio Torigoe, Bruno Casaes Teixeira, and Thomas Laurent are employees of Bristol Myers Squibb and own stocks in Bristol Myers Squibb.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study used de-identified claims\/electronic medical records data and did not require ethics committee review or informed consent. Permission was obtained to access and use data from both the JMDC and DeSC databases.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}